T
Trevor Cox
Researcher at University of Liverpool
Publications - 81
Citations - 4808
Trevor Cox is an academic researcher from University of Liverpool. The author has contributed to research in topics: Alkaptonuria & Pancreatic cancer. The author has an hindex of 30, co-authored 81 publications receiving 3817 citations. Previous affiliations of Trevor Cox include Heidelberg University & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Time-dependent ROC curve analysis in medical research: current methods and applications
TL;DR: The value of time-dependent ROC curve methods has been re-established and some recommendations for future research are made.
Journal Article
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
John P. Neoptolemos,Malcolm J. Moore,Trevor Cox,Juan W. Valle,Daniel H. Palmer,Alec McDonald,Rodney William Carter,Niall C. Tebbutt,Christos Dervenis,D. Smith,Bengt Glimelius,Richard Charnley,François Lacaine,Scarfe Ag,Middleton,Alan Anthoney,Paula Ghaneh,Christopher Halloran,Markus M. Lerch,Attila Oláh,Charlotte L. Rawcliffe,Caroline S. Verbeke,Fiona Campbell,M.W. Büchler +23 more
TL;DR: Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, compared with observation, was not associated with a significant survival Benefit in the primary analysis; however, multivariable analysis adjusting for prognostic variables demonstrated a statistically significant survival benefit associated with adjuant chemotherapy.
Journal ArticleDOI
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
John P. Neoptolemos,Malcolm J. Moore,Trevor Cox,Juan W. Valle,Daniel H. Palmer,A. C. McDonald,Ross Carter,Niall C. Tebbutt,Christos Dervenis,David Smith,Bengt Glimelius,Richard Charnley,François Lacaine,Andrew Scarfe,Mark R. Middleton,Alan Anthoney,Paula Ghaneh,Christopher Halloran,Markus M. Lerch,Attila Oláh,Charlotte L. Rawcliffe,Caroline S. Verbeke,Fiona Campbell,Markus W. Büchler +23 more
TL;DR: In this article, the hazard ratio for chemotherapy compared with observation was 0.75 (95% CI, 0.57-0.98; 2 = 1.33; P=.25).
Journal ArticleDOI
Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study
Juan W. Valle,Daniel H. Palmer,Richard J. Jackson,Trevor Cox,John P. Neoptolemos,Paula Ghaneh,Charlotte L. Rawcliffe,Claudio Bassi,Deborah D. Stocken,David Cunningham,Derek A. O'Reilly,David Goldstein,Bridget A. Robinson,Christos S. Karapetis,Andrew Scarfe,François Lacaine,Juhani Sand,Jakob R. Izbicki,Julia Mayerle,Christos Dervenis,Attila Oláh,Giovanni Butturini,Pehr Lind,Mark R. Middleton,Alan Anthoney,K Sumpter,Ross Carter,Markus W. Büchler +27 more
TL;DR: Completion of all six cycles of planned adjuvant chemotherapy rather than early initiation was an independent prognostic factor after resection for pancreatic adenocarcinoma and there seems to be no difference in outcome if chemotherapy is delayed up to 12 weeks, thus allowing adequate time for postoperative recovery.
Journal ArticleDOI
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
William Greenhalf,Paula Ghaneh,John P. Neoptolemos,Daniel H. Palmer,Trevor Cox,Richard F. Lamb,Elizabeth Garner,Fiona Campbell,John R. Mackey,Eithne Costello,Malcolm J. Moore,Juan W. Valle,A. C. McDonald,Ross Carter,Ross Carter,Niall C. Tebbutt,David Goldstein,Jennifer Shannon,Christos Dervenis,Bengt Glimelius,Mark Deakin,Richard Charnley,François Lacaine,Andrew Scarfe,Mark R. Middleton,Alan Anthoney,Christopher Halloran,Julia Mayerle,Attila Oláh,Richard J. Jackson,Charlotte L. Rawcliffe,Aldo Scarpa,Claudio Bassi,Markus W. Büchler +33 more
TL;DR: Subject to prospective validation, gemcitabine should not be used for patients with low tumor hENT1 expression.